3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
97
Precursor Cell Lymphoblastic Leukemia-Lymphoma
61
Myelodysplastic Syndromes
52
Recurrence
37
Leukemia, Lymphocytic, Chronic, B-Cell
37
Multiple Myeloma
36
Lymphoma, Non-Hodgkin
35
Lymphoma
34
Lymphoma, B-Cell
29
Hematologic Neoplasms
28
Lymphoma, Follicular
24
Lymphoma, Large B-Cell, Diffuse
23
Melanoma
22
Lymphoma, Mantle-Cell
22
Leukemia
22
Lymphoma, B-Cell, Marginal Zone
20
Myeloproliferative Disorders
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
19
Leukemia, Biphenotypic, Acute
18
Hodgkin Disease
18
Ovarian Neoplasms
17
Burkitt Lymphoma
17
Pancreatic Neoplasms
16
Neoplasms
13
Neoplasm Metastasis
12
Leukemia, Myelomonocytic, Chronic
12
Colorectal Neoplasms
11
Anemia, Refractory, with Excess of Blasts
11
Stomach Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Interventions
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
dinutuximab
6
Topotecan
5
Isotretinoin
5
Doxorubicin
5
Biopsy
5
sargramostim
4
Vincristine
4
Stem Cell Transplantation
4
Specimen Handling
4
Radiation
4
Platinum
4
Melphalan
4
Colony-Stimulating Factors
4
Cisplatin
4
Carboplatin
4
1,2-diaminocyclohexaneplatinum II citrate
4
Thiotepa
3
Temozolomide
3
Irinotecan
3
Etoposide
3
Congresses as Topic
3
3-Iodobenzylguanidine
3
etoposide phosphate
2
Razoxane
2
Dexrazoxane
2
Busulfan
2
lorlatinib
1
iberdomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ganglioneuroblastoma
×
fludarabine
×
1 year
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled